Table 3 Results from clinical trials of PD-1/PD-L1 blockade in B-cell lymphoma
From: Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Identifier | B-cell lymphoma | Antibody, dose | Clinical significance | References |
|---|---|---|---|---|
Anti-PD-1 monoclonal antibody | ||||
NCT02332668 | R/R HL (n = 15) | Pembrolizumab 2 mg/kg q3w | ORR 60%, CR 13%, PR 47% | [99] |
NCT03155425 | R/R cHL (n = 75) | Camrelizumab 200 mg q2w | ORR 76%, CR 28%, PR 48% | [100] |
NCT02961101 NCT03250962 | R/R cHL (n = 86) | Camrelizumab 200 mg q3w or Decitabine 10 mg/d, d1-5 + Camrelizumab 200 mg, d8 q3w | Camrelizumab (n = 19): CR 32% Decitabine + Camrelizumab (n = 42): CR 71% | [101] |
NCT03114683 | R/R cHL (n = 96) | Sintilimab 200 mg q3w | ORR 80.4%, CR 34%, PR 47% | [102] |
NCT03209973 | R/R cHL (n = 70) | Tislelizumab 200 mg q3w | ORR 87.1%, CR 62.9% 9 months: PFS 74.5% | [103] |
NCT01953692 | R/R PMBCL (n = 21) | Pembrolizumab 10 mg/kg q2w (n = 10) 200 mg q3w (n = 11) | ORR 48%, CR 33%, PR 14% | [104] |
NCT02332980 | R/R CLL (n = 16) RT DLBCL (n = 9) | Pembrolizumab 200 mg q3w | ORR 16% (CLL:0%, DLBCL:44%) CR (DLBCL) 11%, PR (DLBCL) 22% | [105] |
Anti-PD-L1 monoclonal antibody | ||||
NCT02401048 | R/R FL (n = 27) R/R DLBCL (n = 34) | Ibrutinib 560 mg qd + Durvalumab 10 mg/kg q2w | ORR (all patients) 25% ORR (FL) 26% ORR (GCB DLBCL) 13% ORR (non‐GCB DLBCL) 38% CR (FL) 4% CR (GCB DLBCL) 6% CR (non-GCB DLBCL) 31% median PFS 4.6 months median OS 18.1 months | [106] |
NCT02541604 | HL (n = 9) NHL (n = 3) | Atezolizumab 15 mg/kg (≤ 18 years) Atezolizumab 1200 mg (18-29 years) | PR (HL) 22.2% PR (NHL) 33.3% | [107] |